UNE FORMULATION DE POUDRE SÈCHE INHALABLE COMPRENANT DE GLP-1 POUR L'UTILISATION DANS LE TRAITEMENT DE L'HYPERGLYCÉMIE ET DU DIABÈTE PAR ADMINISTRATION PULMONAIRE
An inhalable dry powder formulation comprising a therapeutically effective amount of a glucagon-like peptide-1 (GLP-1) for prandial use in combination with insulin for the treatment of hyperglycemia and/or diabetes in a patient. The inhalable dry powder formulation preferably comprises a diketopiperazine having the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine and wherein X is selected from the group consisting of succinyl, glutaryl, maleyl, and fumaryl, or a pharmaceutically acceptable salt thereof. The GLP-1 may be selected from the group consisting of native GLP-1, a GLP-1 metabolite, a GLP-1 analog, a GLP-1 derivative, a GLP-1 mimetic, an exendin, a GLP-1 peptide analog, a biosynthetic GLP-1 analog, or combinations thereof.
